Cilnidipine
 | |
| Clinical data | |
|---|---|
| Trade names | Atelec (アテレック), Cilaheart, Cilacar |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.162.338  |
| Chemical and physical data | |
| Formula | C27H28N2O7 |
| Molar mass | 492.528 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
Cilnidipine is a calcium channel blocker. Cilnidipine is approved for use in Japan, China, India, Nepal, Korea, and some European countries to treat hypertension.
It is a calcium antagonist accompanied with L-type and N-type calcium channel blocking functions. Unlike other calcium antagonists, cilnidipine can act on the N-type calcium channel in addition to acting on the L-type calcium channel.
It was patented in 1984 and approved for medical use in 1995.[1]
Medical uses
Cilnidipine decreases blood pressure and is used to treat hypertension and its comorbidities. Due to its blocking action at the N-type and L-type calcium channel, cilnidipine dilates both arterioles and venules, reducing the pressure in the capillary bed. Cilnidipine is vasoselective and has a weak direct dromotropic effect, a strong vasodepressor effect, and an arrhythmia-inhibiting effect. Blood pressure control with cilnidipine treatment in Japanese post-stroke hypertensive patients [The CA-ATTEND study] - the results of a large-scale prospective post-marketing surveillance study of post-stroke hypertensive patients (n = 2667, male 60.4%, 69.0 ± 10.9 years) treated with cilnidipine indicate that cilnidipine was effective in treating uncontrolled blood pressure and was well tolerated in post-stroke hypertensive patients.[2] The Ambulatory Blood Pressure Control and Home Blood Pressure (Morning and Evening) Lowering By N-Channel Blocker Cilnidipine (ACHIEVE-ONE) trial is a large-scale (n=2319) clinical study on blood pressure (BP) and pulse rate (PR) in the real world with use of cilnidipine - this study revealed that Cilnidipine significantly reduced BP and PR in hypertensive patients at the clinic and at home, especially with higher BP and PR in the morning.[3]
Side effects
The side effects could be severe dizziness, fast heartbeat, and swelling of face, lips, tongue, eyelids, hands and feet. Lesser side effects include stomach pain, diarrhea and hypotension.
Peripheral edema, a common side effect from the use of amlodipine, was reduced when patients were shifted to cilnidipine.[4]
Brand Name
In India, it is sold under the brand name cilacar, clinblue, among others at doses of 5mg/10mg/20mg.[5]
History
It was jointly developed by Fuji Viscera Pharmaceutical Company and Ajinomoto, and was approved to enter the market and be used as an anti-hypertensive in 1995.
References
- ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 466. ISBN 9783527607495.
- ↑ Aoki S, Hosomi N, Nezu T, Teshima T, Sugii H, Nagahama S, et al. (2017). "Blood pressure control with cilnidipine treatment in Japanese post-stroke hypertensive patients: The CA-ATTEND study". Clinical and Experimental Hypertension. 39 (3): 225–234. doi:10.1080/10641963.2016.1235183. PMID 28448181.
- ↑ Kario K, Ando S, Kido H, Nariyama J, Takiuchi S, Yagi T, et al. (February 2013). "The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE". Journal of Clinical Hypertension. 15 (2): 133–42. doi:10.1111/jch.12042. PMID 23339732.
- ↑ Minami J, Kawano Y, Makino Y, Matsuoka H, Takishita S (December 2000). "Effects of cilnidipine, a novel dihydropyridine calcium antagonist, on autonomic function, ambulatory blood pressure and heart rate in patients with essential hypertension". British Journal of Clinical Pharmacology. 50 (6): 615–20. doi:10.1046/j.1365-2125.2000.00299.x. PMC 2015014. PMID 11136301.
- ↑ "Cilacar (Cilnidipine): Uses, Side Effects, Dosage - Medical Dialogues". Medical Dialogues. 3 March 2021. Retrieved 3 March 2021.
Further reading
- Löhn M, Muzzulini U, Essin K, Tsang SY, Kirsch T, Litteral J, et al. (May 2002). "Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C". Journal of Hypertension. 20 (5): 885–93. doi:10.1097/00004872-200205000-00023. PMID 12011649. S2CID 30765257.